Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Hua Linda Cai · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $155,866 — ABSTRACT The central focus of this Administrative Supplement application to is to identify detailed molecular mechanisms of estrogen-dependent sex difference in COVID-19 to enable development of novel therapeutics that are in urgent need to control the pandemic. The outbreak of coronavirus disease 2…
Mohammed Bouziane · SUNOMIX THERAPEUTICS · 2022 · $252,010 — SUMMARY Over the last 25 months humanity has been confronting COVID-19 pandemic caused by the new Corona Virus 2 (SARS-CoV-2) infection. Mutations and deletions often occur in the genome of SARS-CoV-2 (predominantly in the Spike protein) resulting in more transmissible and pathogenic “variants of co…
GILL DIAMOND · UNIVERSITY OF MISSISSIPPI MED CTR · 2022 · $822,036 — Abstract Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a life-threatening illness with multi-system involvement in a subset of infected individuals. Oral and nasopharyngeal (NP) epithelial cells express the SARS-CoV-2 receptor…
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2022 · $9,754,127 — FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the …
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2022 · $439,437 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for continuing implementation of the first COVID-19 vaccine efficacy trial “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Stud…
Kiesha Wilson · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · 2022 · $100,000 — PROJECT SUMMARY/ABSTRACT The virus, SARS-CoV-2 has caused COVID-19 and claimed the lives of over 240,000 Americans and 1,270,000 people worldwide. Severe cases of the disease leads to Acute Respiratory Distress Syndrome (ARDS), sepsis and can be fatal due to pulmonary inflammation and destruction of…
Eliver Ghosn · EMORY UNIVERSITY · 2022 · $232,232 — Project Summary Mounting an effective antibody response against SARS-CoV-2 is key to fight off the infection. However, not all antibodies produced against the virus are protective. Recent studies show that high titers of immunoglobulin G (IgG) against the SARS-CoV-2 Spike (S) protein during natural…
Robert Tarran · ELDEC PHARMACEUTICALS, INC. · 2022 · $300,000 — PROJECT SUMMARY COVID-19 is caused by inhalation of the latest coronavirus (CoV) SARS-CoV-2 into the lungs, and airway epithelia are particularly susceptible to uptake this virus. Extensive evidence indicates that angiotensin converting enzyme 2 (ACE2) binds to the S1 subunit of the SARS-CoV-2 Spik…
John YJ Shyy · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2022 · $683,289 — Project Summary Vascular endothelial cell (EC) metabolism is essential for functional endothelium, and maladapted energy use severely affects EC health. AMP-activated protein kinase (AMPK) is a key regulator of cellular energy status and homeostatic function. Our preliminary studies showed that ener…
Haichao Wang · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · 2022 · $418,750 — PROJECT SUMMARY Microbial infections annually claim hundreds of thousands of victims in the U.S. alone, but its complex pathogenesis is still poorly understood. Our seminal discovery of HMGB1 as a late mediator of lethal endotoxemia (Science, 1999, Cited >4,000 times) has fueled continuous search fo…
Daniel Kulp · WISTAR INSTITUTE · 2022 · $228,788 — Project Summary This revised application was originally responding to the Emergency Award ‘Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)’ submitted through PAR-20-177. However, we are submitting the revised application, up…
Margaret M Stratton · UNIVERSITY OF MASSACHUSETTS AMHERST · 2022 · $312,941 — PROJECT SUMMARY How does a memory outlast the lifetime of the molecule that encodes it? More than two decades ago, Francis Crick had the foresight to speculate that perhaps a multimeric protein could serve as a molecular memory by sharing its activation state with newly synthesized proteins through …
Renren Wen · VERSITI BLOOD HEALTH, INC. · 2022 · $659,871 — Abstract COVID-19 severity/lethality is associated with a dysfunctional inflammatory immune response and a hyper- engagement of pathways driving hemostasis and thrombosis, but the link between the two manifestations is not understood. Compared to patients with mild symptoms, severe COVID-19 patients…
Jim Rotolo · SAPIENCE THERAPEUTICS, INC. · 2022 · $288,178 — ABSTRACT The COVID-19 pandemic, caused by the SARS-CoV-2 virus, is a serious threat to global public health, necessitating the rapid development of safe and effective medical countermeasures. SARS-CoV-2 pathogenicity requires a series of protein-protein interactions (PPI) involving the virus’ S prot…
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2022 · $31,284 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…
Diana Carolina Vanegas-Gamboa · CLEMSON UNIVERSITY · 2022 · $426,004 — Project Summary The devastation caused by emerging pathogens with fast transmission capacity, such as SARS-CoV-2, has demonstrated the importance of preparedness for future viral outbreaks; this includes the ability for fast deployment of in-situ testing tools and epidemiological surveillance with h…
Dan H. Barouch · BETH ISRAEL DEACONESS MEDICAL CENTER · 2022 · $725,409 — ABSTRACT The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, a critical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans. Our preliminary data suggest that antibodies correlate with protection following vaccina…
Samuel Matthew Young · UNIVERSITY OF IOWA · 2022 · $154,500 — Project Summary/Abstract Synapses are the fundamental unit of information transfer in the central nervous system (CNS) and are composed a highly complex molecular machinery that tightly regulates synaptic transmission and neuronal circuit output. A multitude of combinations of synaptic proteins and …
GARY B RUVKUN · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $431,960 — Project Summary/Abstract: Our discovery that the NGLY1/PNG-1 deglycosylation enzyme mediates the protein editing of N- glycosylated asparagines to aspartic acid of the SKN-1A transcription factor to increase proteasomal capacity is highly relevant to protein aggregation diseases, such as Alzheimer’s…
Hsien Wei YEH · UNIVERSITY OF WASHINGTON · 2022 · $80,225 — úú PROJECT SUMMARY/ABSTRACT Delivering diagnostic services at the point-of-care (POC) can improve the quality of healthcare in clinics, in emergency settings, or at home, which can potentially ease hospitals’ burden, for instance, during the COVID- 19 pandemic. Precision and personalized medicine re…